A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia
NCT00210795 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2011-06-10
Summary
The purpose of this study is to assess changes in physical function in elderly patients (\>= 65 years of age) with chronic anemia (Hb \<= 11.0 g/dL) due to anemia of unknown cause and receiving weekly subcutaneous doses of Epoetin alfa (PROCRIT®) versus placebo
Conditions
- Anemia
- Aged
- Hemoglobins
Interventions
- DRUG
-
epoetin alfa
Sponsors & Collaborators
-
Ortho Biotech Products, L.P.
collaborator INDUSTRY -
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
lead INDUSTRY
Principal Investigators
-
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-06-30
- Completion
- 2005-10-31
More Related Trials
-
A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
NCT00338468 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)
NCT00307814 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
NCT00337935 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease
NCT00641589 ·Status: COMPLETED ·Phase: PHASE1
-
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
NCT00258440 ·Status: TERMINATED ·Phase: NA
-
Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis
NCT00123149 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.
NCT00212875 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
NCT00446602 ·Status: WITHDRAWN ·Phase: PHASE2
-
Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)
NCT00211120 ·Status: TERMINATED ·Phase: PHASE4
-
PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
NCT00440466 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Chronic Anemia With Epoetin Alfa in Elderly
NCT00337441 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients
NCT00246298 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins
NCT00211029 ·Status: COMPLETED
-
A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies
NCT00210977 ·Status: WITHDRAWN
-
Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia
NCT00954486 ·Status: WITHDRAWN ·Phase: NA
-
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
NCT01290328 ·Status: TERMINATED ·Phase: NA
-
Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease
NCT00579046 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin
NCT00210951 ·Status: COMPLETED
-
An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
NCT00317902 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease
NCT01846689 ·Status: UNKNOWN ·Phase: PHASE3
-
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
NCT00364455 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer
NCT00269984 ·Status: COMPLETED ·Phase: PHASE2
-
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
NCT00058331 ·Status: COMPLETED ·Phase: PHASE3
-
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
NCT00286182 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment
NCT00211042 ·Status: COMPLETED